Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Publication

Article

August 6, 2018

Heal

Summer 2018
Volume1
Issue 1

Working Through Cancer-Related Fatigue

About 40 percent of people with cancer are of working age, and typically have a need to maintain their employment throughout their treatment.

AN ESTIMATED 40 PERCENT of people with cancer are of working age, and those who are employed usually need to stay that way during treatment.

Guy Reynolds knows he is a lucky man, not only because of his response to therapy, but also because he works for a company that provided flexibility while he was going through treatment after receiving a diagnosis of esophageal cancer in 2016. He was 59 years old.

The cancer had already metastasized to his liver, and his medical team was hesitant to give him a prognosis, he says. They told him if chemotherapy didn’t work in six months, he would be moved to a clinical trial for immunotherapy.

“You know, it’s the cutting edge that they’re working on,” Reynolds says. “The doctor said if that didn’t work, then I had six months.”

Now more than 22 months from diagnosis, Reynolds has finished nine months of traditional chemotherapy and three weeks of radiation. He remains on Xeloda (capecitabine), a type of chemotherapy, and Herceptin (trastuzumab), a drug used to treat breast cancer that is human epidermal growth factor receptor (HER) 2-positive. About 20 to 30 percent of esophageal cancers are HER2-positive, meaning they carry the oncogene that Herceptin affects.

“The major problem was the tumor in my liver,” says the married father of three. “It was the size of my fist.” Today his liver tumor is undetectable.

Reynolds says he weathered the chemotherapy well, taking time off from his job as a photo editor for The Dallas Morning News just on the days he had chemotherapy and the day after. Even a bout with an irregular heartbeat brought on by the chemotherapy didn’t keep him down.

Of course, that was before he began radiation.

“I was doing radiation at 9 a.m. and going to work at 9:45 a.m.,” Reynolds says. “By noon I was wiped out. So, I took some short-term medical leave for around 11 weeks.” He returned to work on a split shift that allows him to go home in the middle of the day for a few hours’ sleep.

“After the radiation, they told me that the fatigue would be worse for two to three months,” Reynolds says, “but it’s getting better. I even sat at work today and I thought, ‘You know what, I’m just going to stay here and work straight through.’ And then about an hour later I thought, ‘No, I’m going to go home and take my nap.’”

FINDING YOUR WAY

He was fortunate to find tremendous support at work, especially from his managing editor, who had lost a sister to cancer. Reynolds was even allowed to go for chemotherapy without using paid time off. “They just said ‘go,’ ” Reynolds recalls.

Patients and survivors must find their own ways to cope with fatigue. When employment is involved, creating a customized approach may involve help from family, friends, co-workers and the federal government by way of the Americans with Disabilities Act and the Rehabilitation Act, both of which ensure that people who have or have had cancer are protected against some types of job discrimination. The Family and Medical Leave Act allows 12 weeks of unpaid, job-protected leave for certain family and medical reasons. A study in The Oncologist reported that 75 percent of employed study participants changed their employment status because of fatigue, and 65 percent of patients indicated that their caregivers took at least one day off work in a typical month.

Each patient responds differently to treatment, depending on the drugs used, the length of treatment, whether they receive radiation and whether their place of employment offers insurance and/or is sympathetic. Some people plan their treatment for Fridays so they can rest over the weekend. Consider asking an employer to provide a parking space closer to the office, allow short breaks to rest or arrange for working from home.

Reynolds is approaching his two-year anniversary from the day of diagnosis. He has outlived the median survival and is hoping to be one of those who continues to beat the odds.

Articles in this issue

Cardiovascular Problems Appear in Endometrial Cancer Survivors Years After Treatment
How to Overcome Cancer-Related Fatigue
Testicular Cancer Survivors at Risk of Late Effects of Chemotherapy
Hearing Loss, Tinnitus Common After Neurotoxic Chemotherapy, Study Finds
Comments From Our Readers on Recent Heal Publications
Working Through Cancer-Related Fatigue
Post-Cancer Fatigue: The Invisible Wound

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of bald man.
Image of Dr. Uboha.
Image of man.
Image of man with black hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Dr. Michael Moore
Related Content
Advertisement
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
April 9th 2025

Breaking Down Treatment Options for Patients With Head and Neck Cancer

Alex Biese
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
Related Content
Advertisement
Image of woman holding her neck.
May 5th 2025

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Ryan Scott
First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma: © stock.adobe.com.
April 24th 2025

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

Alex Biese
The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
April 9th 2025

Breaking Down Treatment Options for Patients With Head and Neck Cancer

Alex Biese
Dr. Lillian L. Siu discussed potential risk factors and treatment strategies associated for patients with head and neck cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.